EVMT News | Roxom Stocks

1 BTC

- USD

Loading market data...

AUM

N/A

Volume

631

Yield

11.86%

Chart Earnings News About Dividends Insider Filings

Evome Medical Technologies Announces Securities IssuancesNEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) announces it has received conditional approval from the TSX Venture Exchange (the “TSXV”) to complete a shares for services transaction with Beacon Securities Limited (“Beacon”) pursuant to ‎which the Company will issue Beacon ‎504,286 ‎common ‎shares of the Company at a deemed price of ‎$0.1983 per share in satisfaction of $100,000 of advisory services. The shares issuable will be subject to a Canadian ‎four-month hold period.‎GlobeNewswire Inc. · Jun 14, 2024

Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company.GlobeNewswire Inc. · Jun 3, 2024

Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition DebtPosting Q1 Financials, Provides Updates on Strong Q2 Posting Q1 Financials, Provides Updates on Strong Q2GlobeNewswire Inc. · May 30, 2024

Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is CancelledNEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship with Evome as an example of its willingness to fund growth companies:GlobeNewswire Inc. · Apr 12, 2024

Evome Sells Simbex R&D Business Unit to Riddell for $4.83M in Cash; Improves Balance Sheet, Reduces Biodex Acquisition DebtNEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) has reached an agreement with EB Sports Corp. (the “Buyer”)‎, the parent company of Riddell Sports Group, an industry leader in football helmet technology and innovation, to sell Simbex LLC (“Simbex”), the Company’s R&D business unit, for approximately $4.83M in cash. The proceeds will be used to pay down Simbex debt and reduce Evome’s acquisition debt to the seller of its operating subsidiary Biodex Rehab Systems, LLC (“Biodex”), strengthening the Company’s balance sheet, as well as increasing focus on revenue and profit growth from the Biodex product line.GlobeNewswire Inc. · Apr 2, 2024

Evome Medical Technologies Punctuates Turn Around Plan with Strong Fourth Quarter Resulting in Positive Annual Adjusted EBITDA for Fiscal Year 2023NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announced today preliminary annual financial results for the year ending December 31, 2023. Because of a strong fourth quarter, the Company generated positive Adjusted EBITDA for 2023.GlobeNewswire Inc. · Apr 1, 2024

Evome Medical Engages ICP Securities Inc. for Automated Market Making ServicesNEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “ Company ” or “ Evome ”) (TSXV: EVMT), is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprietary algorithm, ICP Premium™, for its shares traded on the TSX Venture Exchange (the “TSXV”), in compliance with the policies of the TSXV and other applicable legislation. ICP will receive a fee of C$7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an initial term of four (4) months and shall be automatically renewed for subsequent one (1) month terms (each month called an "Additional Term") unless either party provides at least thirty (30) days written notice prior to the end of the initial term or an Additional Term, as applicable. There are no performance fees contained in the agreement and no stock options or other compensation are being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future.GlobeNewswire Inc. · Feb 27, 2024

Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as ChairmanNEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announces the appointment of two senior healthcare executives to its Board of Directors.‎GlobeNewswire Inc. · Feb 15, 2024

Evome Medical Technologies Executes Non-Binding Letter of Intent to Extend Remaining Simbex Acquisition Debt to June 2025; Increases Sales Targets by 7.5% for Biodex Distribution Contracts; Raises Biodex Product Pricing by 2% for 2024NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) has executed a non-binding letter of intent (LOI) to extend acquisition debt of US$3,294,440 to the sellers of Simbex, LLC (“Simbex”) to June 30, 2025. In exchange for the extensions, the Company intends to grant the Simbex sellers (i) a subordinated security interest in all non-Biodex assets, (ii) a 10% annual interest rate on the amount due from April 14, 2023 to the due date, (iii) cash payments when free cash flow balances of the Company exceed $500,000 after payments to other creditors with priority, and (iv) a waiver from the contractual restriction from holding more than 500,000 common shares of Evome (the “Common Shares”) at any one time. As part of the transaction, Simbex sellers have indicated an intention to convert the 4,640,708 Class A non-voting shares (the “Class A Shares”) still held into Common Shares.GlobeNewswire Inc. · Feb 8, 2024

Evome Medical Technologies Reduces Acquisition Debt, Bolsters Management Team to Support SpaceTeck Knee™ and Reactive Step Trainer 2024 Product Roll-OutNEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the ‎‎‎“Company”) ‎‎‎(TSXV: EVMT) announced it has reduced acquisition bank debt by $535,093 as a result of the sale of Arrowhead Medical, LLC (“Arrowhead”), originally acquired in May 2023 (see News Release dated May 16, 2023). As part of the adjustment, Arrowhead will continue to serve as the exclusive distributor of Biodex products in the Midwest United States and a further $209,171 of intercompany debt will be reduced.GlobeNewswire Inc. · Jan 31, 2024

EVMTInvesco Electric Vehicle Metals Commodity Strategy No K-1 ETF

EVMT

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any EVMT yet.

Related Tickers

Earnings

Dividends

Last · Dec 22Annual

Amount$2.00

Yield11.86%

Annual$2.00

Volume

631